Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice

Not Applicable

• Conditions: rheumatoid arthritis

• Registration Number: JPRN-UMIN000030109
• Lead Sponsor: agasaki University

Brief Summary

Immunological Medicine Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice Masataka Umeda, Tomohiro Koga et al. From other patients to infliximab (IFX) from other biological disease-modifying anti-rheumatic drugs (bDMARDs) among Japanese patients with rheumatoid arthritis (RA) in daily practice. Methods: We examined 24 consecutive RA patient who had not achieved low disease activity (LDA) as the Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS 28 - ESR) despite previous bDMARD therapy in this cohort study. DAS 28 - ESR LDA at 22 weeks post - IFX introduction, by performing univariate analysis. Results: The median DAS 28 - ESR at baseline was 5.41. Sixteen patients (66.7%) had been treated with a tumor necrosis factor inhibitor (TNF - i), and the other eight patients (33.3%) received a non - TNF - i abatacept or tocilizumab) achieved LDA or remission at 22 weeks. Univariate analyses showed that the variable to predict LDA achievement at 22 weeks was tender joints (> 8 counts) at baseline (adjusted odds ratio, 0.10; 95 % confidence interval, 0.01 - 0.63; P = 0.02), whereas the other baseline clinical variables including MTX dosage, disease duration and the previous usage of TNF-i not not associated with LDA achievement. and infection requiring hospitalization was observed in one patient. Conclusion: Switching to IFX is effective to achieve LDA or remission for RA patients refractory to bDMARDs.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-12-01
• Study Completion: 2018-10-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

non

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint in this study was the rate of achievement of LDA or remission at week 22after the introduction of infliximab. The adverse events during the observation period.